Amgen (AMGN): Reducing PT To $193 - Leerink

September 14, 2016 8:39 AM EDT
Get Alerts AMGN Hot Sheet
Price: $145.29 +0.89%

Rating Summary:
    17 Buy, 14 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 28 | Down: 20 | New: 17
Trade AMGN Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Leerink Partners analyst, Geoffrey Porges reiterated his Market Perform rating on shares of Amgen (NASDAQ: AMGN) but cut his price target to $193 from $195 . Based on current trends in the prescription data, continued pricing power, and branded and biosimilar competition, the analyst now forecasts peak Enbrel US sales of $6.7bn and Humira US sales of $15bn in 2021, with varying degrees of erosion following thereafter. Subcutaneous (subq) anti-TNF products have been on the market for nearly two decades and have become entrenched therapeutics.

However, when the analyst factored the entry of biosimilar competitors. The analyst expects them to erode ~30% of revenues (share plus price) and then to continue to take share on an annual basis. This impacts the DCF slightly and reduced the price target to $193.

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $169.30 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Add Your Comment